Skip to content

HMB on muscle function in OA with THA or TKA

An open-label comparative study of 3-hydroxy-3-methylbutyrate between preoperative and postoperative muscle function in osteoarthritic patients with total hip or knee arthroplasty . - HMB-M-OA-HK

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051200094
Enrollment
80
Registered
2020-12-11
Start date
2020-12-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis osteoarthritis, osteoarthritis of the hip, osteoarthritis of the knee

Interventions

make a comparison between preoperative and postoperative muscle function in osteoarthritic patients with total hip or knee arthroplasty who receive postoperative rehaviritation and HMB administration
D019643
arthroplasty,HMB,rehabilitation,muscle function

Sponsors

yasuda tadashi
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Patients with osteoarthritis who undergo total hip or knee arthroplasty 2)Patients who will be able to receive standard postoperative rehabilitation 3)Patients who will be able to receive regular follow-up 4)Female patients at age 65 and more at the time of consent acquisition 5)Patients who have voluntarily consented to participate in this study with their comprehension on thorough explanation of this study

Exclusion criteria

Exclusion criteria: 1)Patients who had taken HMB before consent acquisition 2)Patients who had taken medicine or supplement that may affect muscle function 3) Patients who are not expected to receive the standard recovery rehabilitation at the recovery phase hospital after transfer from our hospital 4)Patients with radiotherapy or chemotherapy, or with treatment with steroid or immunosuppressive drugs 5)Patients with paresis 6)Patients with history of malignancy within the last 5 years 7)Patients with history of unstable angina, cardiac infarction, brain infarction, cerebral hemorrhage, or transient cerebral ischemic attack within the last 6 months 8)Patients with severe diseases in liver, kidney, heart, lung, blood, or endocrine and metabolic systems 9)Patients with or with history of inflammatory joint diseases except osteoarthritis 10)Patients with history of total hip or knee arthroplasty within the last 6 months 11)Patients under consideration of other surgical treatment during the protocol period of this study 12)Patients participating in other interventional or clinical trial 13)Patients who are considered inappropriate as the subjects for this study by the principal investigator or co-investigators

Design outcomes

Primary

MeasureTime frame
TKA: difference in knee extensor strength between the baseline and 3 months postoperatively THA: difference in hip abductor strength between the baseline and 3 months postoperatively

Secondary

MeasureTime frame
Main secondary outcomes: TKA: difference in hip abductor and hip extensor strength between the baseline and 3 months postoperatively THA: difference in hip extensor and knee extensor strength between the baseline and 3 months postoperatively All subjects: A comparison of muscle strength alterations during the first 3 months after total hip or knee arthroplasty between patients with and without preoperative sarcopenia Other secondary outcomes in each subject: Muscle strength, 10 m walking speed, Timed Up and Go test, grip strength, muscle volume, muscle composition,Alterations in the ratio of patients with sarcopenia between the base line and 3 months postoperativ

Contacts

Public ContactUtako Shirono

Kobe City Medical Center General Hospital

ushirono@kcho.jp+81-78-302-4321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026